78 related articles for article (PubMed ID: 1900640)
1. Specific and rapid detection by fluorescent in situ hybridization of bacteria in clinical samples obtained from cystic fibrosis patients.
Hogardt M; Trebesius K; Geiger AM; Hornef M; Rosenecker J; Heesemann J
J Clin Microbiol; 2000 Feb; 38(2):818-25. PubMed ID: 10655391
[TBL] [Abstract][Full Text] [Related]
2. The changing epidemiology of pulmonary infection in children and adolescents with cystic fibrosis: an 18-year experience.
Singh J; Hunt S; Simonds S; Boyton C; Middleton A; Elias M; Towns S; Pandit C; Robinson P; Fitzgerald DA; Selvadurai H
Sci Rep; 2024 Apr; 14(1):9056. PubMed ID: 38643191
[TBL] [Abstract][Full Text] [Related]
3. Occurrence of Burkholderia cepacia in the hospital environment.
Moore JE; McIlhatton B; Buchanan J; Gilpin D; Shaw A; Hall V; Murphy PG; Elborn JS
Ir J Med Sci; 2002; 171(3):131-3. PubMed ID: 15736349
[TBL] [Abstract][Full Text] [Related]
4. Cystic fibrosis and guidelines to assess significance of new colonisers?
Garske L; Moore JE; Crowe MJ; Elborn JS
Ir J Med Sci; 2002; 171(2):116-7. PubMed ID: 12173884
[No Abstract] [Full Text] [Related]
5. Prospects for the prevention and control of pseudomonal infection in children with cystic fibrosis.
Høiby N
Paediatr Drugs; 2000; 2(6):451-63. PubMed ID: 11127845
[TBL] [Abstract][Full Text] [Related]
6. Precipitating Pseudomonas aeruginosa antibodies and antimicrobial therapy in cystic fibrosis patients.
Trancassini M; de Vito D; Cimino G; Antonelli M; Quattrucci S; Cipriani P
Eur J Clin Microbiol Infect Dis; 1996 Apr; 15(4):309-12. PubMed ID: 8781882
[TBL] [Abstract][Full Text] [Related]
7. Role of Pseudomonas aeruginosa lipase in inflammatory mediator release from human inflammatory effector cells (platelets, granulocytes, and monocytes.
König B; Jaeger KE; Sage AE; Vasil ML; König W
Infect Immun; 1996 Aug; 64(8):3252-8. PubMed ID: 8757861
[TBL] [Abstract][Full Text] [Related]
8. Effects of mucoid and non-mucoid Pseudomonas aeruginosa isolates from cystic fibrosis patients on inflammatory mediator release from human polymorphonuclear granulocytes and rat mast cells.
Friedl P; König B; König W
Immunology; 1992 May; 76(1):86-94. PubMed ID: 1321094
[TBL] [Abstract][Full Text] [Related]
9. [Pathogenesis and diagnosis of bacterial airway infections in patients with cystic fibrosis].
Möller AV; van Alphen L; Dankert-Roelse JE; Dankert J
Ned Tijdschr Geneeskd; 1995 Nov; 139(46):2346-9. PubMed ID: 7501072
[No Abstract] [Full Text] [Related]
10. Cystic fibrosis: infection.
Høiby N
Schweiz Med Wochenschr; 1991 Jan; 121(4):105-9. PubMed ID: 1900640
[TBL] [Abstract][Full Text] [Related]
11. Lung infection with alginate-producing, mucoid Pseudomonas aeruginosa in cystic fibrosis.
Pedersen SS
APMIS Suppl; 1992; 28():1-79. PubMed ID: 1449848
[TBL] [Abstract][Full Text] [Related]
12. [Frequency of isolation and drug resistance of bacterial strains isolated from respiratory material in patients with cystic fibrosis].
Rosselli P
Quad Sclavo Diagn; 1986 Sep; 22(3):273-82. PubMed ID: 3112860
[TBL] [Abstract][Full Text] [Related]
13. The approach to Pseudomonas aeruginosa in cystic fibrosis.
Bendiak GN; Ratjen F
Semin Respir Crit Care Med; 2009 Oct; 30(5):587-95. PubMed ID: 19760546
[TBL] [Abstract][Full Text] [Related]
14. [Antibiotic treatment of cystic fibrosis].
de Montalembert M; Berche P; Lenoir G
Ann Pediatr (Paris); 1991 Oct; 38(8):523-8. PubMed ID: 1746849
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
